Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles |
April 19, 2018 | April 2018 Bond Updates |
NEW HAVEN, Conn., April 19, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it will hold an investor event concurrently with the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, from 6:00 p.m. to 7:30 p.m. PT on... |
View more at: https://www.prnewswire.com/news-releases/biohaven-pharmaceuticals-announces-additional-phase-3-rimegepant-data-to-be-released-at-investor-event-held-concurrently-with-the-2018-american-academy-of-neurology-meeting-in-los-angeles-300632726.html |
Related News |
|